Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial

IMPORTANCE: Ranibizumab is a viable treatment option for eyes with proliferative diabetic retinopathy (PDR) through 2 years. However, longer-term results are needed. OBJECTIVE: To evaluate efficacy and safety of 0.5-mg intravitreous ranibizumab vs panretinal photocoagulation (PRP) over 5 years for P...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Ophthalmol
Main Authors: Gross, Jeffrey G., Glassman, Adam R., Liu, Danni, Sun, Jennifer K., Antoszyk, Andrew N., Baker, Carl W., Bressler, Neil M., Elman, Michael J., Ferris, Frederick L., Gardner, Thomas W., Jampol, Lee M., Martin, Daniel F., Melia, Michele, Stockdale, Cynthia R., Beck, Roy W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2018
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6233839/
https://ncbi.nlm.nih.gov/pubmed/30043039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaophthalmol.2018.3255
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados